Dark Classics in Chemical Neuroscience: Mescaline
Open accessThe DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.
Abstract
Archeological studies in the United States, Mexico, and Peru suggest that mescaline, as a cactus constituent, has been used for more than 6000 years. Although it is a widespread cactus alkaloid, it is present in high concentrations in few species, notably the North American peyote ( Lophophora williamsii ) and the South American wachuma ( Trichocereus pachanoi, T. peruvianus, and T. bridgesii ). Spanish 16th century chroniclers considered these cacti “diabolic”, leading to their prohibition, but their use persisted to our days and has been spreading for the last 150 years. In the late 1800s, peyote attracted scientific attention; mescaline was isolated, and its role in the psychedelic effects of peyote tops or “mescal buttons” was demonstrated. Its structure was established by synthesis in 1929, and alternative routes were developed, providing larger amounts for pharmacological and biosynthetic research. Although its effects are attributed mainly to its action as a 5-HT 2A serotonin receptor agonist, mescaline binds in a similar concentration range to 5-HT 1A and α 2A receptors. It is largely excreted unchanged in human urine, and its metabolic products are apparently unrelated to its psychedelic properties. Its low potency is probably responsible for its relative neglect by recreational substance users, as the successful search for structure–activity relationships in the hallucinogen field focused largely on finding more potent analogues. Renewed interest in the possible therapeutic applications of psychedelic drugs may hopefully lead to novel insights regarding the commonalities and differences between the actions of individual classic hallucinogens.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mescaline (6) binds with rather low affinity (Ki) as an agonist at 5HT1A sites (5 µM), 5HT2A/C (6 µM against [3H]-ketanserin), alpha2 (1.4 µM) and TAAR1 (3.3 µM) receptors [9,43].”
From Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. (2021) · cites this paper as [43]
Citations
Cites
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Handbook of Psychopharmacology
(1978) · Springer eBooks · doi:10.1007/978-1-4613-4042-3 · Cited by 1,091
Leysen, J. E., Niemegeers, C. J., Van Nueten, J. M., & Laduron, P. M. (1982) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)14623-3 · Cited by 1,071
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4771-x · Cited by 970
Neural correlates of the LSD experience revealed by multimodal neuroimaging
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L., Kaelen, M., Droog, W., Murphy, K., Tagliazucchi, E., Schenberg, E. E., Nest, T., Orban, C., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518377113 · Cited by 859
Gasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., & Brenneisen, R. (2014) · Journal of Nervous & Mental Disease · doi:10.1097/nmd.0000000000000113 · Cited by 750
Nichols, D. E. (1986) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1986.10472362 · Cited by 563
Research works printed but not linked: 12
- Torres C. M., 2008, Chavín Art, Architecture and Culture, 237
- Sahagún B., Historia General de las Cosas de la Nueva España
- Sharon D., 1972, Flesh of the Gods. The Ritual Use of Hallucinogens, 114
- Cruz-Sánchez G., 1948, Rev. Farmacología Med. Exp., 1, 143
- Gutiérrez-Noriega C., 1050, América Indígena, 10, 215
- Poisson J., 1960, Ann. pharm. franç, 18, 764
- Hulsey D., 2011, J. Bot. Res. Inst. Texas, 5, 677
- Kapadia G. J., 1973, Lloydia, 36, 9
- Prentiss D. W., 1895, Ther. Gazette, 9, 577
- Ellis H., 1898, Contemp. Rev., 73, 130
- Shulgin A. T., 1991, PIHKAL, Phenethylamines I Have Known and Loved. A Chemical Love Story
- Alles G. A., 1957, Neuropharmacology, Trans. 4th Conf.
Cited by
The promises and perils of psychedelic pharmacology for psychiatry
McClure-Begley, T. D., & Roth, B. L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00421-7 · Cited by 194
General and specialized tyrosine metabolism pathways in plants
Xu, J.-J., Fang, X., Li, C., Yang, L., & Chen, X. (2019) · aBIOTECH · doi:10.1007/s42994-019-00006-w · Cited by 152
Dinis-Oliveira, R. J., Pereira, C. L., & da Silva, D. D. (2019) · Current Molecular Pharmacology · doi:10.2174/1874467211666181010154139 · Cited by 100
Mescaline: The forgotten psychedelic
Vamvakopoulou, I. A., Narine, K. A. D., Campbell, I., Dyck, J. R. B., & Nutt, D. J. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109294 · Cited by 121
“Mescaline also binds to the dopamine (DAT), norepinephrine (NET), and serotonin (SERT) transporters but with lower affinity (Table 1) (Páleníček et al., 2008; Kyzar et al., 2012; Rickli et al., 2016; Cassels and Sáez-Briones, 2018).”
BackgroundInfluentialDuan, W., Cao, D., Wang, S., & Cheng, J. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00375 · Cited by 85
Natural product-derived compounds in clinical trials and drug approvals
Butler, M. S., Capon, R. J., Blaskovich, M. A. T., & Henderson, I. R. (2026) · Natural Product Reports · doi:10.1039/d5np00031a · Cited by 98
Mendes, F. R., Costa, C. D. S., Wiltenburg, V. D., Morales-Lima, G., Fernandes, J. A. B., & Filev, R. (2022) · Addiction Neuroscience · doi:10.1016/j.addicn.2022.100025 · Cited by 72
Yuan, J. S., Liu, R., Sheng, S., Fu, H., & Wang, X. (2022) · Frontiers in Plant Science · doi:10.3389/fpls.2022.889370 · Cited by 47
“Tyrosine is the precursor of many metabolites (including tocopherol, plastoquinone and ubiquinone) that are essential to the survival and stress resistance of plants (Kilgore and Kutchan, 2016; Cassels and Sáez-Briones, 2018; Xu et al., 2020).”
BackgroundMolecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans.
Cumming, P., Scheidegger, M., Dornbierer, D., Palner, M., Quednow, B. B., & Martin-Soelch, C. (2021) · Molecules · doi:10.3390/molecules26092451 · Cited by 43
The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology
Mastinu, A., Anyanwu, M., Carone, M., Abate, G., Bonini, S. A., Peron, G., Tirelli, E., Pucci, M., Ribaudo, G., Oselladore, E., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021329 · Cited by 57
“Mescaline is an alkaloid, biosynthetically derived from amino acids, with a chemical structure similar to monoamine neurotransmitters, and psychomimetic activity [85,90].”
BackgroundInfluentialYu, Z., Burback, L., Winkler, O., Xu, L., Dennett, L., Vermetten, E. H. G. J. M., Greenshaw, A. J., Li, X., Milne, M., Wang, F., et al. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1386321 · Cited by 53
“There has been a recent resurgence of interest in psychedelic drugs and their therapeutic potential for the treatment of mental disorders (3 – 6).”
BackgroundPsychedelics for treatment resistant depression: are they game changers?
Kalfas, M., Taylor, R. H., Tsapekos, D., & Young, A. H. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2281582 · Cited by 40
“However, mescaline is a low potent psychedelic and a dose of about 300 mg is needed for a full-scale psychedelic experience [42].”
BackgroundDiscovery of β-Arrestin-Biased 25CN-NBOH-Derived 5-HT2AReceptor Agonists
Poulie, C. B. M., Pottie, E., Simon, Í. A., Harpsøe, K., D’Andrea, L., Komarov, I. V., Gloriam, D. E. I., Jensen, A. A., Stove, C. P., & Kristensen, J. L. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00702 · Cited by 34
Klaiber, A., Schmid, Y., Becker, A., Straumann, I., Erne, L., Jelušić, A., Thomann, J., Luethi, D., & Liechti, M. E. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03116-2 · Cited by 32
“The selected range covers doses from very low to very high, based on previous studies with mescaline [2, 12, 14 – 16].”
BackgroundThe mechanistic divide in psychedelic neuroscience: An unbridgeable gap?
Barksdale, B. R., Doss, M. K., Fonzo, G. A., & Nemeroff, C. B. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00322 · Cited by 28
Cacti for production of metabolites: current state and perspectives
Santos-Díaz, M. D. S., & Camarena-Rangel, N. G. (2019) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-019-10125-5 · Cited by 26
Elucidation of the mescaline biosynthetic pathway in peyote (Lophophora williamsii)
Watkins, J. L., Li, Q., Yeaman, S., & Facchini, P. J. (2023) · The Plant Journal · doi:10.1111/tpj.16447 · Cited by 26
Thomann, J., Ley, L., Klaiber, A., Liechti, M. E., & Duthaler, U. (2022) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2022.114980 · Cited by 24
Pharmacologic Similarities and Differences Among Hallucinogens
Waters, K. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1917 · Cited by 21
Kleffens, M. D.-V., Zimmermann-Klemd, A. M., & Gründemann, C. (2023) · Molecules · doi:10.3390/molecules28247942 · Cited by 25
“In fact, however, a slight structural change leads to much more potent molecules [67].”
BackgroundArtru, E., & Rabeyron, T. (2021) · L Évolution Psychiatrique · doi:10.1016/j.evopsy.2021.03.013 · Cited by 22
The biosynthetic pathway of the hallucinogen mescaline and its heterologous reconstruction
Berman, P., de Haro, L. A., Cavaco, A.-R., Panda, S., Dong, Y., Kuzmich, N. N., Lichtenstein, G., Peleg, Y., Harat, H., Jóźwiak, A. P., et al. (2024) · Molecular Plant · doi:10.1016/j.molp.2024.05.012 · Cited by 17
Carvalho, A., Barbosa, B. M., Flores, J. S., Gonçalves, P. D. C., Diniz, R., Cordeiro, Y., Fernández, C. O., Cukierman, D. S., & Rey, N. A. (2022) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2022.112033 · Cited by 17
A Complete Review of Mexican Plants with Teratogenic Effects
Chamorro, G., Mojica-Villegas, M. A., García-Martínez, Y., Pérez‐Gutiérrez, S., Madrigal‐Santillán, E., Vargas-Mendoza, N., Morales‐González, J. A., & Cristóbal-Luna, J. M. (2022) · Plants · doi:10.3390/plants11131675 · Cited by 22
Psychedelics: From Cave Art to 21st-Century Medicine for Addiction
Vamvakopoulou, I. A., & Nutt, D. J. (2024) · European Addiction Research · doi:10.1159/000540062 · Cited by 18
“The mescaline-containing peyote cactus ( Lophophora wil-liamsii; [77]) has been used for centuries by natives in Mexico and North America [2].”
Schwelm, H. M., Zimmermann, N., Scholl, T., Penner, J., Autret, A., Auwärter, V., & Neukamm, M. A. (2021) · Journal of Analytical Toxicology · doi:10.1093/jat/bkab038 · Cited by 13
The Alkaloids from Lophophora diffusa and Other “False Peyotes”
Chan, C. B., Poulie, C. B. M., Wismann, S. S., Soelberg, J., & Kristensen, J. L. (2021) · Journal of Natural Products · doi:10.1021/acs.jnatprod.1c00381 · Cited by 13
Alkaloids of the Cactaceae — The Classics
Cassels, B. K. (2019) · Natural Product Communications · doi:10.1177/1934578x1901400123 · Cited by 13
“Lundström and Agurell [25], and reproduced in our recent review on mescaline [16].”
BackgroundMethodSelf-citationAltered States of Consciousness During Ceremonial San Pedro Use
Bohn, A., Kiggen, M. H. H., Uthaug, M. V., van Oorsouw, K. I. M., Ramaekers, J. G., & van Schie, H. T. (2022) · International Journal for the Psychology of Religion · doi:10.1080/10508619.2022.2139502 · Cited by 12
“Mescaline, for instance, has been found to also act on 5HT2C receptors, as well as on adrenergic, cholinergic, and dopaminergic neurotransmitter systems (Cassels & Sáez-Briones, 2018; Dinis-Oliveira et al., 2019; Kovacic & Somanathan, 2009; Nichols, 2004; Trulson et al., 1983).”
BackgroundSerotonin 2C receptors are also important in head-twitch responses in male mice
Custodio, R. J. P., Ortiz, D. M., Lee, H. J., Sayson, L. V., Buctot, D., Kim, M., Lee, Y. S., Cheong, J. H., Cheong, J. H., & Kim, H. J. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06482-9 · Cited by 16
“…D1R ( K i ≥ 14 µM)), D2R ( K i ≥ 10 µM), D3R ( K i ≥ 17 µM), H1R ( K i ≥ 25 µM), TAAR1 RAT ( K i = 3.3 µM), and TAAR1 MOUSE ( K i = 11 µM)) (Benington et al. 1954; Cassels and Sáez-Briones 2018; Gurschler 2019; Halber-stadt et al. 2019; Páleníček et al. 2008; Rickli et al. 2015; Trulson et al.…”
InfluentialPerfil fitoquímico e atividade antioxidante de flores e frutos de Pereskia aculeata Miller
de Moraes, T. V., Montenegro, J., Marques, T. S., Evangelista, L. M., Rocha, C. B., Teodoro, A. J., Kato, L., & Moreira, R. F. A. (2021) · Scientia Plena · doi:10.14808/sci.plena.2021.051503 · Cited by 24
Călina, D. C., Carvalho, F. D., & Docea, A. O. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85215-9.00022-2 · Cited by 11
Barman, R., Bora, P. K., Saikia, J., Konwar, P., Sarkar, A., Kemprai, P., Saikia, S. P., Haldar, S., Slater, R. J., & Banik, D. (2023) · Phytochemistry · doi:10.1016/j.phytochem.2023.113928 · Cited by 9
Safety pharmacology of acute mescaline administration in healthy participants
Klaiber, A., Humbert‐Droz, M., Ley, L., Schmid, Y., & Liechti, M. E. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16349 · Cited by 9
Hallucinogen Use and Misuse in Older Adults
Redden, W. M., Paracha, S.-U.-R., & Sheheryar, Q. (2021) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2021.07.007 · Cited by 8
In Vitro and In Vivo Evaluation of Pellotine: A Hypnotic Lophophora Alkaloid
Poulie, C. B. M., Chan, C. B., Parka, A., Lettorp, M., Vos, J., Raaschou, A., Pottie, E., Bundgaard, M. S., Sørensen, L. M. E., Cecchi, C. R., et al. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00142 · Cited by 8
Lin, J., Yang, S., Ji, J., Xiang, P., Wu, L., & Chen, H. (2023) · Frontiers in Plant Science · doi:10.3389/fpls.2023.1066595 · Cited by 8
“It is a phenethylamine analogue, and mescaline intoxication produces psychosis-like symptoms, including changes in mood and sensory perception, disturbances of thought and the visual sphere, impaired tactile perception, hypersensitivity to noises, alterations in motor and physical perception, changes in spatial and te…”
BackgroundBiased Signaling in Psychedelic Action
Wacker, D., & McCorvy, J. D. (2025) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-062124-012545 · Cited by 10
Therapeutic Use of Hallucinogens
Wiltenburg, V. D., Prado, D. D. R., & Mendes, F. R. (2021) · Springer eBooks · doi:10.1007/978-3-030-62855-0_35 · Cited by 8
Predescu, I.-A., Jîjie, A.-R., Pătrașcu, D., Pasc, A.-L.-V., Piroș, E. L., Trandafirescu, C. M., Oancea, C. I., Dehelean, C. A., & Moacă, E.-A. (2025) · Pharmacy · doi:10.3390/pharmacy13010007 · Cited by 15
Mueller, L., Klaiber, A., Ley, L., Becker, A., Thomann, J., Luethi, D., Schmid, Y., & Liechti, M. E. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-025-01544-x · Cited by 8
Introduction to the chemistry and pharmacology of psychedelic drugs
Walker, S. R., Pullella, G. A., Piggott, M., & Duggan, P. J. (2023) · Australian Journal of Chemistry · doi:10.1071/ch23050 · Cited by 6
Hallucinogens—psychedelics and dissociative drugs
Petersen, M., Garg, U. C., & Ketha, H. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815846-3.00016-8 · Cited by 6
Padró, J., Panis, D. N. D., Luisi, P., Dopazo, H., Szajnman, S. H., Hasson, E., & Soto, I. M. (2022) · Scientific Reports · doi:10.1038/s41598-022-17118-x · Cited by 6
Hallucinogens and Psychedelics
Jenkins, A. J., & Gates, M. J. (2020) · Springer eBooks · doi:10.1007/978-3-030-42917-1_26 · Cited by 5
5-HT2CR Is as Important as 5-HT2AR in Inducing Hallucinogenic Effects in Serotonergic CompoundsPreprint
Custodio, R. J. P., Ortiz, D. M., Lee, H. J., Sayson, L. V., Buctot, D. B., Kim, M., Lee, Y. S., Kim, K., Cheong, J. H., & Kim, H. J. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4121838 · Cited by 5
Powder-George, Y. L., Kukula-Koch, W. A., & Widelski, J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18657-8.00005-0 · Cited by 4
Chibli, L. A., de Lima, B. R., Carneiro, A. M., Figueiró, H. C., Çiçek, S. S., Spiegler, V., & Funari, C. S. (2024) · Journal of Natural Products · doi:10.1021/acs.jnatprod.3c01048 · Cited by 4
Rached, G., Campana, A. M., Fiani, D., Nguyen, C. Y., den Eynde, V. V., Gillman, P. K., & Barnett, B. S. (2026) · CNS Drugs · doi:10.1007/s40263-025-01256-7 · Cited by 3
Effects of congeners of amphetamine on the human heart
Neumann, J., Dhein, S., Kirchhefer, U., Hofmann, B., & Gergs, U. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-02983-2 · Cited by 3
“A review of plants producing mes-caline (from tyrosine) is recommended for details (Cassels and Sáez-Briones 2018).”
BackgroundMethodInfluentialNeurological Effects of Stimulants and Hallucinogens
Hass, R. M., & Stitt, D. W. (2024) · Seminars in Neurology · doi:10.1055/s-0044-1787572 · Cited by 4
Steroids, Dissociatives, Club Drugs, Inhalants, and Hallucinogens
Khan, M., Semaan, A., & Thomas, A. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-33404-8_13 · Cited by 3
Mazzoni, I. E. (2021) · Springer eBooks · doi:10.1007/978-3-030-79293-0_2 · Cited by 3
Design and synthesis of beta-Arrestin-biased 5HT2AR agonists
D’Andrea, L. (2023) · VBN Forskningsportal (Aalborg Universitet) · doi:10.54337/aau528157052 · Cited by 6
Żełabowski, K., Biedka, K., Pichowicz, W., Sterkowicz, M., Radzka, I., Ilski, I., Wesołowski, M., Wojtysiak, K., Petrov, W., Ślebioda, D., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18101555 · Cited by 3
“Effects are associated with temporary improvements in mood, which can be made permanent under the right conditions of use [30].”
Psychoactive plants and phytochemicals
Salem, M. A., Zayed, A., & Ezzat, S. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821556-2.00028-1 · Cited by 4
N,N‐Diformylmescaline: A novel analogue of mescaline detected in Queensland
Gallagher, R., McLaughlin, M. G., Blakey, K., Wermuth, U. D., Boyd, S. E., & McGowan, J. (2022) · Drug Testing and Analysis · doi:10.1002/dta.3390 · Cited by 2
Breaking bad buttons: mescaline biosynthesis in peyote
Kirschner, G. K. (2023) · The Plant Journal · doi:10.1111/tpj.16503 · Cited by 2
Toxicodynamic insights of 2C and NBOMe drugs – Is there abuse potential?
Gil-Martins, E., Barbosa, D. J., Borges, F., Remião, F., & Silva, R. V. D. S. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.101890 · Cited by 4
“1), a naturally present psychedelic phenethylamine in several species of cacti [5].”
The Promise of Psychedelic Research
Peritore, C. (2022) · Future Drug Discovery · doi:10.4155/fdd-2021-0012 · Cited by 3
BIODIVERSITY, CULTURE AND BIOECONOMY IN LATIN AMERICA
Ardisana, E. F. H., & Gaínza, B. M. (2022) · CHAKIÑAN REVISTA DE CIENCIAS SOCIALES Y HUMANIDADES · doi:10.37135/chk.002.18.14 · Cited by 5
“This is not the only plant that produces mescaline, since several South American species of the genus Trichocereus also synthesize this alkaloid (Cassels & Sáez 2018).”
BackgroundPlant Poisons, Hallucinogens, and Traditional Medicines
Aronson, J. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-7020-7959-7.00080-4 · Cited by 1
Chan, C. B., Pottie, E., Simon, Í. A., Rossebø, A. G., Herth, M. M., Harpsøe, K., Kristensen, J. L., Stove, C. P., & Poulie, C. B. M. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00667 · Cited by 1
Vogt, S. B., & Liechti, M. E. (2025) · International review of neurobiology · doi:10.1016/bs.irn.2025.02.003 · Cited by 2
León, F., Zakid, A. A., Gupta, S., Mukhopadhyay, S., Tarawneh, A. H., Obeng, S., Cutler, S. J., & McCurdy, C. R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-95702-1.00490-5 · Cited by 1
The DOPA scaffold: Tracing catechol chemistry from prebiotic earth to cognitive agency
Alachkar, A. (2025) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2025.10.004 · Cited by 1
Pottie, E., & Stove, C. P. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108094 · Cited by 2
Adli Toksikoloji: Temel Kavramlar ve Prensipler
Bavunoğlu, I., Genç, M. K., Yayla, M., Açıkkol, M., Zengin, S., Şimşek, S. Z., Bülbül, T. T., & Arslan, Z. (2024) · doi:10.5152/6400 · Cited by 1
Adli Toksikolojide Analiz Yöntemleri
Bülbül, T. T., & Türkmen, Z. (2024) · doi:10.5152/6406 · Cited by 1
Bhadoria, P., Tiwari, A., Jain, A. K., & Ramanathan, V. (2024) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2024.124562 · Cited by 1
Klassieke psychedelica: veiligheid, neveneffecten en medicatie-interacties
Geleyn, E., Kuypers, K. P. C., Seynaeve, M., & Lemmens, G. M. D. (2023) · Tijdschrift voor Geneeskunde · doi:10.47671/tvg.79.23.049
Toksik Maddelerin Sınıflandırılması
Genç, M. K., Bülbül, T. T., Şimşek, S. Z., Arslan, Z., Zengin, S., & Türkmen, Z. (2024) · doi:10.5152/6404 · Cited by 2
Adli Toksikolojinin Tanımı ve Tarihsel Gelişimi
Açıkkol, M. (2024) · doi:10.5152/6401 · Cited by 1
Adli Toksikolojide Yasal Uygulamalar ve Raporlama
Açıkkol, M. (2024) · doi:10.5152/6408
Adli Toksikoloji Laboratuvarı ve Yöntem Geçerliliği
Bülbül, T. T., Yayla, M., & Mercan, S. (2024) · doi:10.5152/6407
Zehirlenmelere Adli ve Klinik Yaklaşım
Bavunoğlu, I. (2024) · doi:10.5152/6403
Mercan, S., & Zengin, S. (2024) · doi:10.5152/6402
Adli Toksikolojide Kullanılan Deliller ve Numune Hazırlama Yöntemleri
Zengin, S., Kuloglu, M., TÜRKMEN, Z., & Mercan, S. (2024) · doi:10.5152/6405
Adli Toksikolojide Yenilikçi Yaklaşımlar
Şimşek, S. Z., Kuloglu, M., & Mercan, S. (2024) · doi:10.5152/6409
Corrigendum to: Introduction to the chemistry and pharmacology of psychedelic drugs
Walker, S. R., Pullella, G. A., Piggott, M., & Duggan, P. J. (2024) · Australian Journal of Chemistry · doi:10.1071/ch23050_co · Cited by 3
L’Heureux, A., Muhlfelder, D., & Dyck, E. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197760864.003.0009
Vlotinou, P., Christodoulou, K., Tsiakiri, A., Christidi, F., & Serdari, A. (2025) · Brazilian Journal of Science · doi:10.14295/bjs.v4i10.785
Toscano, M. O., Civardi, S. C., & Durbano, F. (2025) · Pharmaceutical science. · doi:10.5772/intechopen.1014070
Behnam, H., Ghasemnezhad, A., Alizadeh, M., & Mahonak, A. S. (2026) · Research Square · doi:10.21203/rs.3.rs-11112710/v1
BindingDB Entry 50017411: The Alkaloids from
BindingDB (2023) · UC San Diego · doi:10.7270/q2ks6wkg
BindingDB Entry 50016203: Discovery of β-Arrestin-Biased 25CN-NBOH-Derived 5-HT
BindingDB (2023) · UC San Diego · doi:10.7270/q2wd44j5
Metadata
- Authors
- Cassels, B. K., & Sáez-Briones, P.
- Affiliations
- University of Chile (CL)
- Laboratory of Neuropharmacology and Behavior, School of Medicine, Faculty of Medical Sciences, Universidad de Santiago de Chile, Santiago 9170022, Chile
- Corresponding author
- Cassels, Bruce K.
- ORCID
- Cassels, Bruce K.
- Venue
- ACS Chemical Neuroscience
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-05-30
- Volume
- 9
- Issue
- 10
- Pages
- 2448-2458
- ISSN
- 1948-7193 (ISSN-L)
- OpenAlex
- W2806747726
- Cited by
- 85
- References
- 126
- Citations by year
- 2026: 3 · 2025: 13 · 2024: 12 · 2023: 25 · 2022: 14 · 2021: 11 · 2020: 3 · 2019: 3 · 2018: 1
- FWCI
- 0.76
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by-nc-nd
- Locations
- ACS Chemical Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Universidad de Chile (submittedVersion, cc-by-nc-nd)
- Funders
- Departamento de Investigaciones Cient?ficas y Tecnol?gicas, Universidad de Santiago de Chile (021701SB)
- Fondo Nacional de Desarrollo Cient?fico y Tecnol?gico (1150686)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Alkaloids: synthesis and pharmacology
- Physical Sciences › Chemistry › Organic Chemistry › Synthesis and bioactivity of alkaloids
- Keywords
- mescaline, peyote, Lophophora williamsii, cactus alkaloids, psychedelics, 5-HT2A receptor agonism, 5-HT1A receptor, alpha2A-adrenergic receptor, structure-activity relationship
- MeSH terms
- Hallucinogens, Humans, Mescaline, Structure-Activity Relationship, History, 16th Century, History, 19th Century, History, 20th Century, History, 21st Century, History, Ancient
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.